| | 股份 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 920101 | 志高 | 2025.08.14 | 231.19 | 1536.58 | 1.31 | 0.00 | | | 机械 | | | | | | | 301632 | 广东 | 2025.08.12 | 418.45 | 4970.94 | 2.12 | 0.00 | | | 建科 | | | | | | | 920007 | 酉立 | 2025.08.08 | 246.89 | 639.16 | 0.72 | 0.00 | | | 智能 | | | | | | | 603406 | 天富 | 2025.08.08 | 140.68 | 5699.63 | 2.82 | 0.00 | | | 龙 | | | | | | | 301491 | 汉桑 | 2025.08.06 | 186.72 | 7481.88 | 3.33 | 0.00 | | | 科技 | | | | | | | 920005 | 鼎佳 | 2025.07.31 | 479.12 | 425.51 | ...

9月25日晚间，北京证券交易所(简称"北交所")上市委员会今年第24次审议会议结果出炉，蘅东光通讯 技术(深圳)股份有限公司(简称"蘅东光")符合发行条件、上市条件和信息披露要求。 蘅东光主营业务为光通信领域无源光器件产品的研发、制造与销售，主要业务板块包括无源光纤布线、 无源内连光器件及相关配套业务三大板块。 招股书披露，蘅东光拟募集资金近5亿元，分别用于桂林制造基地扩建(三期)项目、越南生产基地扩建 项目、总部光学研发中心建设项目、补充流动资金。 2022年至今年上半年，蘅东光的营业收入和净利润整体呈上升趋势。尤其是自2024年以来公司业绩增长 迅速，今年上半年同比继续大增100%以上。 公司业绩实现快速增长，主要因为境外销售大幅增长。2022年至2024年，公司外销收入占主营业务收入 比例从75%升至90%左右，占比逐年增加。 同日，北交所披露奥美森智能装备股份有限公司(简称"奥美森")申购结果，有效申购户数近60万户，网 上获配比例为0.022%，冻结资金超7000亿元。 此外，当日浙江锦华新材料股份有限公司(简称"锦华新材")在北交所上市，系浙江省国资国企中首家在 北交所上市的企业。 近期，北交所新 ...

北交所近期上市新股首日涨跌幅 | 代码 | 简称 | 发行价（元） | 上市日期 | 首日收盘价（元） | 首日涨跌幅（%） | | --- | --- | --- | --- | --- | --- | | 920015 | N锦华 | 18.15 | 2025.09.25 | 42.29 | 133.00 | | 920022 | 世昌股份 | 10.90 | 2025.09.19 | 40.50 | 271.56 | | 920100 | 三协电机 | 8.83 | 2025.09.08 | 78.20 | 785.62 | | 920112 | 巴兰仕 | 15.78 | 2025.08.28 | 48.15 | 205.13 | | 920056 | 能之光 | 7.21 | 2025.08.22 | 32.04 | 344.38 | | 920018 | 宏远股份 | 9.17 | 2025.08.20 | 42.00 | 358.02 | | 920101 | 志高机械 | 17.41 | 2025.08.14 | 57.66 | 231.19 | | 920007 | 酉立智能 | 23.99 ...

北交所新股N锦华（920015）今日上市，开盘上涨114.88%，截至上午收盘涨幅扩大至147.99%，半日成 交量2409.42万股，成交额9.50亿元，换手率77.64%。 公司本次公开发行数量为3266.67万股，发行价格为18.15元，发行市盈率11.52倍，网上发行量为2613.33 万股。根据超额配售选择权机制，浙商证券已向网上投资者超额配售490.00万股，占初始发行股份数量 的15.00%，同时网上发行数量扩大至3103.33万股。本次发行战略配售股份合计653.33万股，占初始发 行规模的20.00%。 本次网上发行有效申购数量4689736.69万股，有效申购倍数为1511.19倍，有效申购 户数为52.49万户，网上获配比例为0.07%。（数据宝） （文章来源：证券时报网） 证券时报·数据宝统计显示，公司主要从事酮肟系列精细化学品的研发、生产和销售。 2022年、2023年、2024年公司净利润分别为7959.22万元、1.73亿元、2.11亿元。 ...

N锦华（920015）今日在北交所上市，开盘价39.00元，上涨114.88%。 公司主要从事酮肟系列精细化学品的研发、生产和销售。公司上市申请获北交所受理日期为2024年6月 21日，从受理到今日上市，累计用了461天。 证券时报·数据宝统计显示，公司本次公开发行数量为3266.67万股，发行价格为18.15元，发行市盈率 11.52倍，网上发行量为2613.33万股。根据超额配售选择权机制，浙商证券已向网上投资者超额配售 490.00万股，占初始发行股份数量的15.00%，同时网上发行数量扩大至3103.33万股。本次发行战略配 售股份合计653.33万股，占初始发行规模的20.00%。 本次网上发行有效申购数量4689736.69万股，有效 申购倍数为1511.19倍，有效申购户数为52.49万户，网上获配比例为0.07%。 2022年—2024年公司净利润分别为7959.22万元、1.73亿元、2.11亿元。（数据宝） 近期北交所上市新股首日开盘涨跌幅 | 代码 | 简称 | 上市日期 | 发行价 | 网上申购获配比例 | 上市首日开盘价 | 上市首日开盘涨跌幅 | | --- | --- | --- ...

Core Insights - Three companies have recently been listed on different stock exchanges, with their respective issuance prices and price-earnings ratios provided [1][2][3][4]. Group 1: Company Listings - Jianfa Zhixin was listed on the Shenzhen Stock Exchange's ChiNext with a stock code of 301584, an issuance price of 7.05 CNY per share, and a price-earnings ratio of 13.29 [2]. - United Power was listed on the Shenzhen Stock Exchange's ChiNext with a stock code of 301656, an issuance price of 12.48 CNY per share, and a price-earnings ratio of 32.87 [3]. - Jinhua New Materials was listed on the Beijing Stock Exchange with a stock code of 920015, an issuance price of 18.15 CNY per share, and a price-earnings ratio of 11.95 [4]. Group 2: Company Profiles - Jianfa Zhixin specializes in the direct sales and distribution of medical devices and provides centralized operation services for medical consumables to hospitals [2]. - United Power aims to be a global leader in intelligent electric vehicle components and solutions, focusing on core components of power systems such as electric drive systems and power supply systems [3]. - Jinhua New Materials is engaged in the research, production, and sales of ketoxime series fine chemicals [5].

Group 1: New Stock Performance - The recent performance of new stocks on the Beijing Stock Exchange remains highly active, with the stock of Sanxie Electric rising by over 860% on its first day of trading, closing up 785.62%, marking the highest first-day increase of the year [1] - Aifenda also saw a first-day increase of 170.03%, with a single subscription yield exceeding 16,000 yuan [1] Group 2: Upcoming IPOs - This week, there are five new stocks available for subscription, including three from the Growth Enterprise Market, one from the Shenzhen Main Board, and one from the Beijing Stock Exchange [3] - The first stock available for subscription on September 15 is United Power, a leader in the new energy vehicle power system industry, collaborating with major automotive brands [1][5] Group 3: Financial Projections - United Power expects to achieve a net profit of 750 million to 900 million yuan in the first three quarters of 2025, representing a year-on-year growth of 31.05% to 57.26% [5] - The projected revenue for United Power in the same period is between 1.4 billion and 1.55 billion yuan, indicating a growth of 30.62% to 44.61% compared to the previous year [6] Group 4: Other Companies' Projections - Jianfa Zhixin anticipates a net profit of 200 million to 222 million yuan for the first three quarters of 2025, reflecting a growth of 30% to 40% [7] - Jin Hua New Materials expects a decline in revenue to 1.063 billion yuan for the full year 2025, down 14.25%, with a net profit of 199 million yuan, a decrease of 5.47% [9] - Rui Li Ke Mi forecasts a net profit of 196 million to 220 million yuan for the first three quarters of 2025, with a growth rate of 11.96% to 25.67% [10][11] - Yunhan Xincheng projects a net profit of 77 million to 80 million yuan for the first three quarters of 2025, with a growth of 38.71% to 44.11% [12][13]

Group 1 - Company Jianfa Zhixin is offering shares for subscription with a code of 301584, an issue price of 7.05 yuan per share, and a total of 63.19 million shares available [2] - The top subscription requires a market value of 100,000 yuan, with a single account subscription limit of 10,000 shares [2] - The company specializes in direct sales and distribution of medical devices and provides centralized operation services for medical consumables to hospitals [3] Group 2 - Company Jinhua New Materials is also offering shares for subscription with a code of 920015, an issue price of 18.15 yuan per share, and a total of 32.67 million shares available [4] - The top subscription requires a market value of 28.16 million yuan, with a single account subscription limit of 1.55 million shares [4] - The company focuses on the research, production, and sales of ketoxime series fine chemicals [5] Group 3 - The number of winning subscription numbers for You Sheng Co. is 63,982, with each winning number allowing the subscription of 500 shares [6] - The winning numbers are detailed in the announcement, including various combinations of digits [7] - The final winning rate for the online issuance of United Power is 0.0328%, with a total of 13,329,409 valid subscription accounts [8][9]

Core Viewpoint - The company, JinHua New Materials, has initiated its IPO with a price of 18.15 yuan and a P/E ratio of 11.52 times, aiming to raise approximately 5.93 billion yuan for various projects [1][2]. Group 1: IPO Details - The initial issuance quantity is 32.67 million shares, with an online issuance of 26.13 million shares, and a total share capital post-issuance of 131 million shares [1][2]. - The company has authorized Zheshang Securities to allocate an additional 4.90 million shares to online investors, increasing the online issuance to 31.03 million shares [1][2]. - The strategic placement of shares amounts to 6.53 million shares, representing 20% of the initial issuance scale [1][2]. Group 2: Fundraising and Project Allocation - The total expected fundraising amount is 593 million yuan, which could increase to 682 million yuan if the overallotment option is fully exercised [1][2]. - The raised funds will be directed towards several projects, including: - 60kt/a high-end coupling agent project: 506.90 million yuan - Ketoxime silicon new materials research institute: 136.22 million yuan - Intelligent factory construction for the ketoxime industry chain: 63.11 million yuan - Marketing network construction: 38.61 million yuan - 500 tons/year JH-2 pilot project: 23 million yuan [2]. Group 3: Financial Performance - The company’s net profit for 2022, 2023, and 2024 is projected to be 79.59 million yuan, 173 million yuan, and 211 million yuan, respectively, with year-on-year changes of -67.34%, 116.74%, and 22.28% [2]. - Key financial indicators for 2024 include total assets of 1.32 billion yuan, net assets of 842.66 million yuan, and operating income of 1.24 billion yuan [3][4]. - The diluted earnings per share for 2024 is projected at 2.15 yuan, with a return on equity of 28.19% [4].

Group 1: Company Overview - The company operates as a national high-value medical device distributor, focusing on direct sales and distribution of medical devices, as well as providing centralized operation services for medical consumables to hospitals [2] - As of the signing date of the prospectus, Xiamen Jianfa Medical Health Investment Co., Ltd. holds 51.02% of the company's shares, making it the controlling shareholder [2] - The actual controller of the company is the Xiamen State-owned Assets Supervision and Administration Commission, which indirectly holds 51.02% of the company's shares through its ownership of Jianfa Group and Jianfa Medical [2] Group 2: Fundraising and Financials - The company plans to raise approximately 484.24 million yuan for projects including information system upgrades, centralized operation services for medical consumables, and to supplement working capital [2] - The initial public offering (IPO) price is set at 7.05 yuan per share, with an expected total fundraising amount of 445.51 million yuan, and a net fundraising amount of approximately 363.33 million yuan after deducting issuance costs [3] Group 3: Industry Context - The company plays a crucial role in the medical device supply chain, acting as a hub that connects manufacturers, distributors, and end medical institutions [2] - The reference industry price-earnings ratio for the wholesale industry is 25.73, while the company's offering price results in a price-earnings ratio of 13.29, indicating a potential undervaluation compared to industry peers [1]